OneSkin raises $20M in Series A funding for skin longevity research
OneSkin, a biotechnology company focused on skin longevity, will use the $20 million Series A investment round to expand research and development of anti-aging skin care products. The investment round was led by Selva Ventures, with additional support from Unilever Ventures, Able Partners, and additional investors, including model and entrepreneur Camila Alves McConaughey and tech entrepreneur Kevin
Advancing skin longevity science with OS-01 Peptide
Founded in 2016 by four Brazilian scientists, OneSkin specializes in anti-aging solutions targeting cellular aging processes. According to the company, the brand’s core ingredient, OS-01, is a patented peptide that “is the first peptide scientifically proven to reverse skin’s biological age by preventing the accumulation of senescent cells,” contributing to the visible signs of aging.
In a statement on the funding, OneSkin Co-Founder and CEO Dr. Carolina Oliveira said, “At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity.”
According to OneSkin, the funds will allow the company to increase its research capacity and expand its product offerings in the growing skin longevity sector.
Investment to support innovation and market expansion
The Series A funding is expected to support OneSkin in developing additional formulations and expanding its market reach. Dr. Alessandra Zonari, OneSkin’s Co-Founder and Chief Science Officer, commented in a press statement, “This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin.”
Lead investor Selva Ventures cited consumer demand for products that combine beauty and wellness benefits as a factor in its decision to support OneSkin. “We are seeing the beauty and wellness spaces converge as more consumers want efficacious products that make them look and feel their best,” said Madeline Kaplan, partner at Selva Ventures, adding that "OneSkin is well-positioned at the intersection of beauty and wellness, delivering exceptional results that improve both skin appearance and skin health.”
Broader support for scientific advancements in skin care
In addition to institutional investors, OneSkin’s Series A round attracted individual investors, including Brazilian-American model and designer Camila Alves McConaughey. “As a Brazilian woman, I am thrilled to invest in a brand founded by four Brazilian female scientists – my heritage is something I'm incredibly proud of, and I am honored to support those who are executing this work,” McConaughey stated in the press announcement.
The company has reported significant interest in its science-backed approach to skin care and recognition from industry publications. For example, OneSkin was recently named one of Fast Company’s Most Innovative Companies of 2024 for its work in skin health and anti-aging solutions, the company cited in its press announcement.
The investment is notable for manufacturers and suppliers in the cosmetics and personal care sectors, as it reflects a shift toward skin care products with scientifically validated, functional benefits. As OneSkin pursues new formulas and additional distribution channels, the funding may enable the company to broaden access to its anti-aging technology.
